Treatment simplification to once daily darunavir/ ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients

Abstract

Background

We explored a treatment simplification strategy to darunavir/ritonavir 900/100 mg once daily guided by the darunavir virtual inhibitory quotient (vIQ) in patients receiving salvage therapy with darunavir/ ritonavir 600/100 mg twice daily.

Methods

Open-label, randomized pilot study in HIV-infected patients on darunavir/ritonavir 600/100 mg twice daily (viral load <50 copies/ml; darunavir vIQ >2). Thirty patients were randomized to darunavir/ritonavir 900/100 mg once daily (once-daily group, n=15) or 600/100 mg twice daily (twice-daily group, n=15). Viral load, blood chemistry, and darunavir and ritonavir trough plasma concentrations (C_trough) were determined up to 48 weeks. If the darunavir vIQ fell to <1.5, the dosage was switched to 600/100 mg twice daily. The primary end point was the percentage of 48-week treatment failure.

Results

Patients had taken a mean 11.6 (sd ±3.9) antiretro-viral regimens before darunavir/ritonavir administration. The proportion of patients without 48-week treatment failure was 86.7% in both groups. The median (interquartile range [IQR]) darunavir C_trough decreased from 3.09 mg/l (IQR 2.43–3.93) at baseline to 1.60 mg/l (IQR 1.25–2.04) at week 48 (P=0.001) in the once-daily group. Three once-daily group patients switched to darunavir/ritonavir 600/100 mg twice daily. Fewer patients had triglyceride levels >200 mg/ dl at week 48 in the once-daily group (20.0%) than in the twice-daily group (20.0% versus 57.1%; P=0.046).

Conclusions

Treatment simplification to darunavir/ ritonavir 900/100 mg once daily guided by the darunavir vIQ in treatment-experienced HIV-infected patients receiving darunavir/ritonavir 600/100 mg twice-daily seems to be safe enough to be tested in adequately powered clinical trials.

References

Dierynck

, De Wit

, Gustin

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.

J Virol 2007; 81: 13845–13851.

Rinehart

A.R.

, Picchio

, de Béthune

M.P.

Prevalence of darunavir resistance-associated mutations in samples received for routine clinical resistance testing. 5th European HIV Drug Resistance Workshop. 28–30 March 2007, Cascais, Portugal. Abstract 44.

Prezista (darunavir). Package insert 2009. Janssen-Cilag International NV

Beerse, Belgium.

Sekar

, Spinosa-Guzman

, Lefebvre

, Hoetelmans

Clinical pharmacology of TMC114 – a new protease inhibitor. 16th International AIDS Conference. 13–18 August 2006, Toronto, Canada. Abstract TUPE0083.

Rittweger

, Aratéh

Clinical pharmacokinetics of darunavir.

Clin Pharmacokinet 2007; 46: 739–756.

Clotet

, Bellos

, Molina

J.M.

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Lancet 2007; 369: 1169–1178.

Haubrich

, Berger

, Chiliade

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

AIDS 2007; 21: F11–F18.

Mills

A.M.

, Nelson

, Jayaweera

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

AIDS 2009; 23: 1679–1688.

de Meyer

, Spinosa-Guzman

, Vangeneugden

, de Béthune

M.P.

, Miralles

Efficacy of darunavir (DRV)/r 800/100mg qd in patients with low DRV resistance. 5th European HIV Drug Resistance Workshop. 28–30 March 2007, Cascais, Portugal. Abstract 48.

10.

de Meyer

S.M.

, Spinosa-Guzman

, Vangeneugden

T.J.

, de Béthune

M.P.

, Miralles

G.D.

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir.

J Acquir Immune Defic Syndr 2008; 49: 179–182.

11.

Arribas

J.R.

, Horban

, Gerstoft

The MONET trial: darunavir/ritonavir monotherapy shows non-inferior efficacy to standard HAART, for patients with HIV RNA <50 copies/mL at baseline. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract TUAB106-LB.

12.

Cahn

, Fourie

, Grinsztein

Efficacy and safety at 48 weeks of once-daily vs twice-daily DRV/r in treatment-experienced HIV-1⁺ patients with no DRV resistance-associated mutations: the ODIN trial. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Fransisco, CA, USA. Abstract 57.

13.

Sekar

, de Meyer

, Vangeneugden

T.J.

Pharmacokinetic/pharmacodynamic (PK/PD) analyses of TMC114 in the POWER 1 and 2 trials in treatment-experienced HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections. 5–9 February 2006, Denver, CO, USA. Abstract J-121.

14.

Moltó

, Santos

J.R.

, Pérez-Alvarez

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Antimicrob Agents Chemother 2008; 52: 3928–3932.

15.

Droste

J.A.

, Aarnoutse

R.E.

, Koopmans

P.P.

Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

J Acquir Immune Defic Syndr 2003; 32: 287–291.

16.

Hoefnagel

J.G.M.

, Koopmans

P.P.

, Burger

D.M.

Role of the inhibitory quotient in HIV therapy.

Antivir Ther 2005; 10: 879–892.

17.

Johnson

V.A.

, Brun-Vézinet

, Clotet

Update of the drug resistance mutations in HIV-1: December 2008.

Top HIV Med 2008; 16: 138–145.

18.

Boffito

, Miralles

, Hill

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.

HIV Clin Trials 2008; 9: 418–427.

19.

Moyle

The Assessing Patients’ Preferred Treatments (APPT-1) study.

Int J STD AIDS 2003; 14 Suppl 1: 34–36.

20.

Madruga

J.V.

, Berger

, McMurchie

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Lancet 2007; 370: 49–58.